Abstract
The protective effect of purified human immunoglobulin against human T-cell leukaemia virus type I (HTLV-I), designated ATLIG on HTLV-I infection was examined in cynomolgus monkeys ( Macaca fascicularis) as a preclinical study. Passive immunization of ATLIG 24 h before challenging HTLV-I protected the monkeys from HTLV-I infection. The result suggests that passive immunization of ATLIG could provide safe and sufficient protection against HTLV-I infection in humans.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
